Larsen, Thomas Stauffer5; Iversen, Katrine F.5; Hansen, Esben6; Mathiasen, Anders Bruun7; Marcher, Claus Werenberg5; Frederiksen, Mikael8; Larsen, Herdis9; Rasmussen, Inge Helleberg1; Riley, Caroline Hasselbalch10; Bjerrum, Ole Weis7; Rønnov-Jessen, Dorthe11; Møller, Michael Boe12; de Stricker, Karin12; Vestergaard, Hanne5; Hasselbalch, Hans Carl6
1 Aalborg University Hospital, The Faculty of Medicine, Aalborg University, VBN2 Klinik Medicin, The Faculty of Medicine, Aalborg University, VBN3 Blodsygdomme (Hæmatologi), The Faculty of Medicine, Aalborg University, VBN4 The Faculty of Medicine, Aalborg University, VBN5 Department of Hematology, Odense University Hospital, Odense, Denmark.6 Department of Hematology, Roskilde Sygehus7 Department of Hematology, Rigshospitalet, Copenhagen, Denmark.8 Department of Internal Medicine, Hematology, Haderslev Hospital9 Department of Internal Medicine, Hematology, Viborg Hospital10 Department of Hematology, Herlev Hospital, Herlev, Denmark.11 Department of Internal Medicine, Hematology, Vejle12 Department of Clinical Pathology and Molecular Biology, Odense University Hospital
Within recent years data has accumulated demonstrating the efficacy of recombinant interferon alpha2 (rIFN-alpha2) in the treatment of chronic myeloproliferative neoplasms (MPNs). We report on clinical and molecular data in the largest cohort of JAK2 V617F mutant MPN Danish patients (n=102) being treated long-term with rIFN-alpha2 (rIFN-alpha2a and rIFN-alpha2b in a non-clinical trial setting. The median follow-up was 42 months. We substantiate the capacity of rIFN-alpha2 to induce complete hematologic remissions (ET 95%, PV 68%) and molecular response. In total 76 patients (74.5%) had a decline in JAK2 V617F allele burden with a median reduction from baseline of 59% (95% c.i. 50-73%, range 3-99%). A decline in JAK2 V617F allele burden was recorded in both ET (median 24-10% (95% c.i.: 8-16%), and PV (median 59-35% (95% c.i.: 17-33%). Patients with the lowest pre-treatment JAK2 V617F allele burdens tend to achieve the most favourable responses on long term treatment with rIFN-alpha2. Eleven patients (10%) had deep molecular remissions with ≤ 2% JAK2 V617F mutant DNA. Finally, long term treatment with rIFN-alpha2 was associated with a very low thrombosis rate. Our observations are supportive of the concept of early up-front treatment with rIFN-alpha2.
Leukemia Research, 2013, Vol 37, Issue 9, p. 1041-1045